The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial.

被引：44

作者：

Burnett, Alan K.

Kell, William J.

Goldstone, Anthony H.

Milligan, Donald

Hunter, Ann

Prentice, Archie G.

Russell, Nigel H.

Gibson, Brenda

Wheatley, Keith

Hills, Robert K.

机构：

[1] Univ Cardiff Wales, Welsh Sch Med, Cardiff, Wales

[2] N London Canc Network, London, England

[3] Birmingham Heartlands Hosp, Birmingham, W Midlands, England

[4] Leicester Royal Infirm, Leicester, Leics, England

[5] City Hosp Nottingham, London, England

[6] Yorkhill Royal Hosp Sick Children, Glasgow, Lanark, Scotland

[7] Univ Birmingham, Clin Trials Unit, Birmingham, W Midlands, England

来源：

关键词：

D O I：

10.1182/blood.V108.11.18.18

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：8A / 8A

页数：1